JP2021168603A - Blastocyst formation promoting agent - Google Patents

Blastocyst formation promoting agent Download PDF

Info

Publication number
JP2021168603A
JP2021168603A JP2020072222A JP2020072222A JP2021168603A JP 2021168603 A JP2021168603 A JP 2021168603A JP 2020072222 A JP2020072222 A JP 2020072222A JP 2020072222 A JP2020072222 A JP 2020072222A JP 2021168603 A JP2021168603 A JP 2021168603A
Authority
JP
Japan
Prior art keywords
blastocyst
medium
extract
garlic
fertilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020072222A
Other languages
Japanese (ja)
Inventor
太一 原
Taichi Hara
幸 有賀
Miyuki Ariga
勝成 諸富
Masanari Morotomi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tenshindo Co Ltd
Waseda University
Original Assignee
Tenshindo Co Ltd
Waseda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenshindo Co Ltd, Waseda University filed Critical Tenshindo Co Ltd
Priority to JP2020072222A priority Critical patent/JP2021168603A/en
Priority to CN202180025143.6A priority patent/CN115605582A/en
Priority to PCT/JP2021/015451 priority patent/WO2021210609A1/en
Publication of JP2021168603A publication Critical patent/JP2021168603A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/064Saccharomycetales, e.g. baker's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

To provide a novel blastocyst formation promoting agent.SOLUTION: A blastocyst formation promoting agent comprises yeast fermented garlic or an extract thereof.SELECTED DRAWING: None

Description

本発明は、受精卵から胚盤胞への形成促進剤に関する。 The present invention relates to an agent for promoting the formation of a fertilized egg into a blastocyst.

ヒトを含む哺乳類の卵が卵管内で受精してから子宮に着床するまでの間に受精卵は、2個、4個、8個のように細胞分裂し、卵管内を移動しながら桑実胚、胞胚、そして胚盤胞へと分化していく。体外受精においては、培地中で卵子に精子を添加し、体外で胞胚又は胚盤胞まで培養して子宮内に戻す。 Between the time when the eggs of mammals including humans are fertilized in the oviduct and the time when they are implanted in the uterus, the fertilized eggs divide into cells like 2, 4, and 8 and move in the oviduct while morula. It differentiates into embryos, blastocysts, and blastocysts. In in vitro fertilization, sperm are added to an egg in a medium, and the blastocyst or blastocyst is cultured in vitro and returned to the endometrium.

ここで、体外受精においては、妊娠率の向上には健康な卵子と精子の提供が必要とされるが、受精から着床までの段階における胚盤胞への形成率は極めて重要である。この胚盤胞の形成率の向上は、正常な妊娠率の向上のうえでも重要とされる。
特に、マウスの体外受精においては、2細胞まで分裂した後、細胞分裂が進行しなくなる現象、2cell blockが知られており、受精率は向上しても、胚盤胞への形成率が低ければ、妊娠率は向上しない(非特許文献1)。
Here, in in vitro fertilization, it is necessary to donate healthy eggs and sperms in order to improve the pregnancy rate, but the rate of formation into blastocysts in the stage from fertilization to implantation is extremely important. This improvement in the blastocyst formation rate is also important for improving the normal pregnancy rate.
In particular, in in vitro fertilization of mice, a phenomenon in which cell division does not proceed after dividing up to 2 cells, 2 cell block, is known. , The pregnancy rate does not improve (Non-Patent Document 1).

一方、アリイン、アリシンを含まない無臭ニンニクが精子数、精子運動率を増強すること(特許文献1)、ニンニク又はニンニクエキスが雄性生殖管の炎症を低減し、精巣テストステロン濃度を増加させること(特許文献2)、S−アリルシステインが精子数、精子運動率の低下を抑制すること(特許文献3)が知られている。 On the other hand, odorless garlic containing no alliin or allicin enhances sperm count and sperm motility (Patent Document 1), and garlic or garlic extract reduces inflammation of the male reproductive tract and increases testosterone concentration in the testis (Patent). It is known that S-allylcysteine suppresses a decrease in sperm count and sperm motility (Patent Document 3).

特開平11−346712号公報Japanese Unexamined Patent Publication No. 11-346712 特表2008−544994号公報Japanese Patent Publication No. 2008-544994 特開2012−17295号公報Japanese Unexamined Patent Publication No. 2012-17295

Int. J. Dev. Biol. 53:129-134(2009)Int. J. Dev. Biol. 53: 129-134 (2009)

本発明の課題は、受精卵から胚盤胞への形成促進剤及びこれを用いる体外受精用胞胚又は胚盤胞の製造法を提供することにある。 An object of the present invention is to provide an agent for promoting the formation of fertilized eggs into blastocysts and a method for producing in vitro fertilization blastocysts or blastocysts using the same.

そこで、本発明者らは、受精卵から胚盤胞への形成に作用する成分を見出すべく種々検討した結果、酵母発酵ニンニク又はその抽出物が受精卵から胚盤胞への形成を促進する作用を有し、受精卵の着床率向上、ひいては妊娠率向上効果を有することを見出した。また、酵母発酵ニンニク又はその抽出物は、体外受精後の受精卵から胚盤胞形成までの培地成分としても有用であることを見出した。 Therefore, as a result of various studies to find a component that acts on the formation of the fertilized egg into the blastocyst, the present inventors have an action that the yeast fertilized garlic or its extract promotes the formation from the fertilized egg into the blastocyst. It was found that it has an effect of improving the implantation rate of fertilized eggs and, by extension, improving the pregnancy rate. We also found that yeast-fermented garlic or its extract is also useful as a medium component from fertilized eggs to blastocyst formation after in vitro fertilization.

すなわち、本発明は、次の発明[1]から[4]を提供するものである。
[1]酵母発酵ニンニク又はその抽出物を含有する胚盤胞形成促進剤。
[2]受精卵から胚盤胞への形成促進剤である[1]記載の胚盤胞形成促進剤。
[3]酵母発酵ニンニク又はその抽出物を含有する体外受精用培地。
[4]酵母発酵ニンニク又はその抽出物を含有する培地中で卵子と精子を受精させ、次いで当該培地中で受精卵を培養することを特徴とする体外受精用胞胚又は胚盤胞の製造法。
That is, the present invention provides the following inventions [1] to [4].
[1] A blastocyst formation promoter containing yeast fermented garlic or an extract thereof.
[2] The blastocyst formation-promoting agent according to [1], which is a formation-promoting agent from a fertilized egg to a blastocyst.
[3] In vitro fertilization medium containing yeast fermented garlic or an extract thereof.
[4] A method for producing an in vitro fertilized blastocyst or blastocyst, which comprises fertilizing an egg and a sperm in a medium containing yeast fertilized garlic or an extract thereof, and then culturing the fertilized egg in the medium.

本発明によれば、受精卵から胚盤胞への形成を促進する胚盤胞形成促進剤が提供できる。本発明の胚盤胞形成促進剤を受精時及び/又は受精後に適用すれば、受精後の胚盤胞形成が促進されるので、着床率、ひいては妊娠率が向上する。また、本発明の胚盤胞形成剤は、体外受精における、培地成分として有用であり、この培地成分を含有する培地で、受精卵を培養すれば体外受精用胞胚又は胚盤胞の形成が促進され、体外受精における着床率が向上する。 According to the present invention, it is possible to provide a blastocyst formation promoter that promotes the formation of a fertilized egg into a blastocyst. When the blastocyst formation promoter of the present invention is applied at the time of fertilization and / or after fertilization, blastocyst formation after fertilization is promoted, so that the implantation rate and thus the pregnancy rate are improved. Further, the blastocyst forming agent of the present invention is useful as a medium component in in vitro fertilization, and culturing fertilized eggs in a medium containing this medium component promotes the formation of in vitro fertilization blastocysts or blastocysts. And the implantation rate in in vitro fertilization is improved.

酵母発酵ニンニクの抽出物の添加による、2細胞胚形成に対する影響及び胚盤胞形成に対する影響を示す図である。It is a figure which shows the influence on the two-cell embryo formation and the influence on the blastocyst formation by the addition of the extract of yeast fermented garlic.

本発明の胚盤胞形成促進剤の有効成分は、酵母発酵ニンニク又はその抽出物である。 The active ingredient of the blastocyst formation promoter of the present invention is yeast fermented garlic or an extract thereof.

酵母発酵ニンニクの原料として用いるニンニクは、アリウム・サチバム(Allium sativum)の全草・地上部又は鱗茎が好ましく、鱗茎がより好ましい。本発明においては、ニンニク又はその抽出物を直接用いるのではなく、酵母発酵ニンニク又はその抽出物を用いるのが、優れた胚盤胞形成促進効果を得る観点から重要である。 The garlic used as a raw material for yeast-fermented garlic is preferably whole plant / above-ground part or bulb of Allium sativum, and more preferably bulb. In the present invention, it is important to use yeast-fermented garlic or an extract thereof instead of directly using garlic or an extract thereof from the viewpoint of obtaining an excellent blastocyst formation promoting effect.

ニンニクの発酵に用いられる酵母としては、出芽酵母(Saccharomyces cerevisiae)、分裂酵母(シゾサッカロミケス属)、コウジカビとしてAspergillus oryzae、Aspergillus sojae、Aspergillus awamori、Aspergillus glaucus、Penicillium roqueforti、枯草菌としてBacillus属等が挙げられるが、Saccharomyces cerevisiaeがより好ましい。 Saccharomyces cerevisiae, Saccharomyces cerevisiae, Aspergillus oryzae, Aspergillus sojae, Aspergillus awamori, Aspergillus glaucus, Penicillium roqueforti, Aspergillus roqueforti Etc., but Saccharomyces cerevisiae is more preferable.

酵母発酵ニンニクは、例えばニンニクを80℃以上に加熱処理した後、酵母を用いて発酵することにより得ることができる。まず、加熱処理としては、80℃以上であれば雑菌の増殖を抑制できるが、85℃以上が好ましく、80℃〜120℃がより好ましい。また加熱処理時間は、5分〜1時間が好ましく、5分〜30分で十分である。酵母発酵は、酵母を添加し、30〜40℃で2日〜5日行うのが好ましい。なお、発酵には、グルコース等の糖類を添加して行うのが好ましい。発酵の進行は、ニンニク特有の臭いの変化及びpHの低下(pH6以下への低下)によって確認することができる。 Yeast-fermented garlic can be obtained, for example, by heat-treating garlic to 80 ° C. or higher and then fermenting it with yeast. First, as the heat treatment, the growth of various germs can be suppressed at 80 ° C. or higher, but 85 ° C. or higher is preferable, and 80 ° C. to 120 ° C. is more preferable. The heat treatment time is preferably 5 minutes to 1 hour, and 5 minutes to 30 minutes is sufficient. Yeast fermentation is preferably carried out at 30-40 ° C. for 2-5 days with the addition of yeast. Fermentation is preferably carried out by adding sugars such as glucose. The progress of fermentation can be confirmed by the change in odor peculiar to garlic and the decrease in pH (decrease to pH 6 or less).

得られた酵母発酵ニンニクは、そのままでも使用できるが、粉砕処理して粉末として使用することもでき、抽出物として使用することもできる。酵母発酵ニンニク抽出物としては、酵母発酵ニンニクから水、熱水、アルコール等の有機溶媒で抽出した抽出物が挙げられるが、水又は熱水抽出物がより好ましい。抽出手段は、特に限定されず、酵母発酵ニンニク又はその粉砕物に、水等の溶媒を添加して溶媒中に溶解した成分を採取すればよい。溶媒抽出にあたって、加熱等を行ってもよく、ソックスレー抽出等を採用してもよい。 The obtained yeast fermented garlic can be used as it is, but it can also be pulverized and used as a powder, or can be used as an extract. Examples of the yeast-fermented garlic extract include extracts extracted from yeast-fermented garlic with an organic solvent such as water, hot water, and alcohol, but water or hot water extract is more preferable. The extraction means is not particularly limited, and a solvent such as water may be added to the yeast fermented garlic or a pulverized product thereof, and the components dissolved in the solvent may be collected. In solvent extraction, heating or the like may be performed, or Soxhlet extraction or the like may be adopted.

酵母発酵ニンニク又はその抽出物は、後記実施例に示すように、受精から2細胞胚への分裂までにはほとんど作用せず、2細胞胚から胞胚又は胚盤胞への形成を有意に促進する作用を有する。このような作用は、ニンニク又はニンニクに含まれる成分の作用からは、全く予測できないものであった。
従って、酵母発酵ニンニク又はその抽出物は、胚盤胞形成促進剤、特に受精卵から胚盤胞への形成促進剤として有用である。また、酵母発酵ニンニク又はその抽出物は、体外受精用培地の成分としても有用であり、酵母発酵ニンニク又はその抽出物を含有する培地で、受精卵を培養すれば、体外受精用胞胚又は胚盤胞の形成が促進される。
Yeast-fermented garlic or its extract has little effect from fertilization to division into two-cell embryos and significantly promotes the formation of two-cell embryos into blastocysts or blastocysts, as shown in Examples below. Has an action. Such an action was completely unpredictable from the action of garlic or the components contained in garlic.
Therefore, yeast fermented garlic or an extract thereof is useful as a blastocyst formation promoter, particularly as a blastocyst formation promoter from a fertilized egg. In addition, yeast fertilized garlic or its extract is also useful as a component of an in vitro fertilization medium, and if a fertilized egg is cultured in a medium containing yeast fertilized garlic or an extract thereof, an in vitro fertilization blastocyst or blastocyst can be obtained. Blastocyst formation is promoted.

本発明の胚盤胞形成促進剤を受精時及び/又は受精後に適用すれば、受精後の着床率、ひいては妊娠率が向上する。胚盤胞形成促進剤の適用手段としては、ヒトを含む哺乳動物に医薬品、食品組成物、外用組成物として摂取、塗布又は投与する手段、及び体外受精における受精卵に適用する手段が挙げられる。従って、本発明の胚盤胞形成促進剤は、受精卵培養培地への添加剤、医薬品、食品組成物、外用組成物の形態が含まれる。 When the blastocyst formation promoter of the present invention is applied at the time of fertilization and / or after fertilization, the implantation rate after fertilization and thus the pregnancy rate are improved. Examples of the means for applying the blastocyst formation promoter include means for ingesting, applying or administering as a drug, food composition, external composition to mammals including humans, and means for applying to fertilized eggs in in vitro fertilization. Therefore, the blastocyst formation promoter of the present invention includes the form of an additive to a fertilized egg culture medium, a pharmaceutical product, a food composition, and an external composition.

これらの胚盤胞形成促進剤中に、酵母発酵ニンニク又はその抽出物は、乾燥固形分量として0.001〜50質量%含有させるのが好ましく、0.001〜20質量%含有させるのがより好ましい。 The yeast fermented garlic or its extract is preferably contained in these blastocyst formation promoters in an amount of 0.001 to 50% by mass, more preferably 0.001 to 20% by mass as a dry solid content. ..

本発明の胚盤胞形成促進剤を医薬品、食品組成物、外用組成物として使用するにあたっては、通常の食品、医薬品、外用剤などの製剤化で使用される任意成分を含有することができる。この様な任意成分としては、経口投与組成物であれば、例えば、乳糖や白糖などの賦形剤、デンプン、セルロ−ス、アラビアゴム、ヒドロキシプロピルセルロ−スなどの結合剤、カルボキシメチルセルロ−スナトリウム、カルボキシメチルセルロ−スカルシウムなどの崩壊剤、大豆レシチン、ショ糖脂肪酸エステルなどの界面活性剤、マルチト−ルやソルビト−ルなどの甘味剤、クエン酸などの酸味剤、リン酸塩などの緩衝剤、シェラックやツェインなどの皮膜形成剤、タルク、ロウ類などの滑沢剤、軽質無水ケイ酸、乾燥水酸化アルミニウムゲルなどの流動促進剤、生理食塩水、ブドウ糖水溶液などの希釈剤、矯味矯臭剤、着色剤、殺菌剤、防腐剤、香料など好適に例示できる。 When the blastocyst formation promoter of the present invention is used as a pharmaceutical product, a food composition, or an external composition, it may contain an arbitrary component used in the formulation of ordinary foods, pharmaceuticals, external preparations, and the like. As such an optional component, if it is an orally administered composition, for example, an excipient such as lactose or sucrose, a binder such as starch, cellulosic, arabic rubber, hydroxypropylcellulosic, or carboxymethyl cellulosic. Disintegrants such as sodium and carboxymethyl cellulose calcium, surfactants such as soy lecithin and sucrose fatty acid esters, sweeteners such as multitor and sorbitol, acidulants such as citric acid, phosphates, etc. Binders, film-forming agents such as shelac and zein, lubricants such as talc and waxes, flow promoters such as light anhydrous citric acid and dry aluminum hydroxide gel, diluents such as physiological saline and glucose aqueous solutions, Preferable examples include a flavoring agent, a coloring agent, a bactericidal agent, a preservative, and a fragrance.

外用組成物であれば、スクワラン、ワセリン、マイクロクリスタリンワックスなどの炭化水素類、ホホバ油、カルナウバワックス、オレイン酸オクチルドデシルなどのエステル類、オリ−ブ油、牛脂、椰子油などのトリグリセライド類、ステアリン酸、オレイン酸、レチノイン酸などの脂肪酸、オレイルアルコ−ル、ステアリルアルコ−ル、オクチルドデカノ−ル等の高級アルコ−ル、スルホコハク酸エステルやポリオキシエチレンアルキル硫酸ナトリウム等のアニオン界面活性剤類、アルキルベタイン塩等の両性界面活性剤類、モノアルキルアンモニウム塩、ジアルキルアンモニウム塩等のカチオン界面活性剤類、ソルビタン脂肪酸エステル、脂肪酸モノグリセライド、これらのポリオキシエチレン付加物、ポリオキシエチレンアルキルエ−テル、ポリオキシエチレン脂肪酸エステル等の非イオン界面活性剤類、ポリエチレングリコ−ル、グリセリン、1,3−ブタンジオ−ル等の多価アルコ−ル類、増粘・ゲル化剤、酸化防止剤、紫外線吸収剤、色剤、防腐剤等を含有することができる。
製造は、常法に従い、各種の製剤化に適した手段により行うことができる。また、本発明の胚盤胞形成促進剤の形態としては、錠剤、ソフトカプセル、ハードカプセル、顆粒、ドリンク剤、膣用外用剤、ジェリー状外用剤等が好ましい。
For external compositions, hydrocarbons such as squalane, vaseline and microcrystalin wax, esters such as jojoba oil, carnauba wax and octyldodecyl oleate, triglycerides such as olive oil, beef fat and coconut oil, Fatty acids such as stearic acid, oleic acid and retinoic acid, higher alcohols such as oleyl alcohol, stearyl alcohol and octyldodecanol, anionic surfactants such as sulfosuccinate and sodium polyoxyethylene alkyl sulfate. , Amphoteric surfactants such as alkylbetaine salts, cationic surfactants such as monoalkylammonium salts and dialkylammonium salts, sorbitan fatty acid esters, fatty acid monoglycerides, their polyoxyethylene adducts, polyoxyethylene alkylates. Nonionic surfactants such as tell, polyoxyethylene fatty acid ester, polyvalent alcohols such as polyethylene glycol, glycerin, 1,3-butanjiol, thickening / gelling agent, antioxidant, It can contain an ultraviolet absorber, a coloring agent, an antiseptic, and the like.
The production can be carried out by means suitable for various formulations according to a conventional method. Further, as the form of the blastocyst formation promoting agent of the present invention, tablets, soft capsules, hard capsules, granules, drinks, vaginal external agents, jelly-like external agents and the like are preferable.

本発明の胚盤胞形成促進剤を、体外受精用培地の添加剤として使用すれば、受精卵から胚盤胞への形成率が向上した体外受精用培地が得られる。体外受精用培地への酵母発酵ニンニク又はその抽出物の添加量は、乾燥固形分量として0.001〜50質量%が好ましく、0.001〜20質量%がより好ましい。 When the blastocyst formation promoter of the present invention is used as an additive for an in vitro fertilization medium, an in vitro fertilization medium having an improved formation rate from a fertilized egg to a blastocyst can be obtained. The amount of yeast fermented garlic or its extract added to the in vitro fertilization medium is preferably 0.001 to 50% by mass, more preferably 0.001 to 20% by mass as the dry solid content.

酵母発酵ニンニク又はその抽出物を含有する精子前培養培地中で精子を培養し、その後抽出液を含まない培地中で培養後、卵子と精子を受精させ、次いで当該培地中で受精卵を培養すれば、体外受精用胞胚又は胚盤胞が効率よく得られる。 Cultivate sperm in a sperm preculture medium containing yeast fertilized garlic or an extract thereof, then cultivate in a medium containing no extract, fertilize the eggs and sperm, and then cultivate the fertilized eggs in the medium. For example, in vitro fertilization vesicles or scutellum vesicles can be efficiently obtained.

ここで、体外受精用培地としては、通常の体外受精に用いられる培地が挙げられる。例えば、精子の前培養には、CARD FERTIUPTM精子前培養培地(九動、佐賀、日本)が挙げられる。卵子塊の前培養にはCARD MEDIUMTM高性能体外受精用培地(九動、佐賀、日本)が挙げられる。受精卵の培養にはCARD mHTF体外受精用培地(九動、佐賀、日本)を使用する。2細胞胚の培養にはKSOM-AA(MERCK、NJ、USA)が挙げられる。 Here, examples of the medium for in vitro fertilization include a medium used for normal in vitro fertilization. For example, sperm pre-culture includes CARD FERTIUP TM sperm pre-culture medium (Kyudo, Saga, Japan). Preculture of egg mass includes CARD MEDIUM TM high-performance in vitro fertilization medium (Kyudo, Saga, Japan). CARD mHTF in vitro fertilization medium (Kyudo, Saga, Japan) is used for culturing fertilized eggs. Examples of 2-cell embryo cultures include KSOM-AA (MERCK, NJ, USA).

受精手段は、例えば、精子の前培養とその後の体外受精により行われる。精子の前培養培地としては、FERTIUPTM精子前培養培地(九動、佐賀、日本)などが挙げられる。精子は酵母発酵ニンニク又はその抽出物を含有する培地中で、37℃、5%CO2、95%空気条件下で30分間前培養した。その後、FERTIUPTM精子前培養培地中で、37℃、5%CO2、95%空気条件下において60分間培養を行われる。卵子の前培養培地は、CARD MEDIUMTM(九動、佐賀、日本)等が挙げられる。前培養した精子と卵子塊は、CARD mHTF体外受精用培地等の体外受精用培地中で、37℃、5%CO2、95%空気条件下で体外受精が行われる。 The fertilization means is carried out, for example, by pre-culture of sperm and subsequent in vitro fertilization. Examples of the sperm preculture medium include FERTIUP TM sperm preculture medium (Kyudo, Saga, Japan). Sperm were pre-cultured in a medium containing yeast fermented garlic or an extract thereof under 37 ° C., 5% CO 2 , 95% air conditions for 30 minutes. Then, the cells are cultured in FERTIUP TM sperm preculture medium under 37 ° C., 5% CO 2 , 95% air conditions for 60 minutes. Examples of the egg preculture medium include CARD MEDIUM TM (Kyudo, Saga, Japan) and the like. The pre-cultured sperm and egg mass are in vitro fertilized in an in vitro fertilization medium such as CARD mHTF in vitro fertilization medium under 37 ° C., 5% CO 2 , and 95% air conditions.

培養手段は、例えば、前培養した精子と卵子塊を体外受精し、37℃で5%CO2、95%空気条件下で3時間後、受精卵をCARD mHTF体外受精用培地(九動、佐賀、日本)で3回洗浄し、37℃、5%CO2、95%空気条件下で一晩培養する。翌日、2細胞期胚をKSOM-AA(MERCK、NJ、USA)培地移して、37℃で5%CO2、95%空気条件下で3日間培養が行われる。 As a culturing means, for example, pre-cultured sperm and egg mass are in vitro fertilized, and after 3 hours under 5% CO 2 and 95% air conditions at 37 ° C., the fertilized egg is subjected to CARD mHTF in vitro fertilization medium (Kyudo, Saga). , Japan), and incubate overnight at 37 ° C, 5% CO 2 , 95% air conditions. The next day, 2-cell stage embryos are transferred to KSOM-AA (MERCK, NJ, USA) medium and cultured at 37 ° C. under 5% CO 2 and 95% air conditions for 3 days.

このようにして得られた受精卵(4〜8細胞期、胞胚又は胚盤胞)は、子宮に戻される。通常の胚移植は4〜8細胞期に子宮に移植される。また、胚盤胞まで発育させてから移植する胚盤胞移植のほうが着床率が高い。しかし、培養したすべての胚が胚盤胞にならない問題がある。本発明の胚盤胞形成促進剤を用いた体外受精によれば、受精卵から4〜8細胞や胚盤胞への形成が促進されるので、移植に良好な受精卵が形成され、着床率、ひいては妊娠率が向上する。 The fertilized egg (4-8 cell stage, blastocyst or blastocyst) thus obtained is returned to the uterus. Normal embryo transfer is performed in the uterus at the 4-8 cell stage. In addition, the implantation rate is higher in blastocyst transplantation, in which blastocysts are developed and then transplanted. However, there is a problem that not all cultured embryos become blastocysts. According to in vitro fertilization using the blastocyst formation promoter of the present invention, the formation of 4 to 8 cells or blastocysts from the fertilized egg is promoted, so that a fertilized egg that is good for transplantation is formed and implantation. The rate, and thus the pregnancy rate, improves.

次に実施例を挙げて、本発明を更に詳細に説明する。 Next, the present invention will be described in more detail with reference to examples.

製造例1(酵母発酵ニンニク末)
生ニンニクの剥き身100gを、ミキサーを用いてペースト化し、次いで75〜85℃に30分加熱した。次いで、酵母(saccharomyces cerevisiae)を白金耳で植菌しグルコースを添加し、35℃で約3日間発酵させた。85℃に30分加熱して発酵停止した後、凍結乾燥機で48時間凍結乾燥し、酵母発酵ニンニク末を得た(収量30g)。
Production Example 1 (Yeast fermented garlic powder)
100 g of stripped raw garlic was made into a paste using a mixer and then heated to 75-85 ° C. for 30 minutes. Then, yeast (saccharomyces cerevisiae) was inoculated with a platinum loop, glucose was added, and fermentation was carried out at 35 ° C. for about 3 days. After heating to 85 ° C. for 30 minutes to stop fermentation, freeze-drying was performed in a freeze-dryer for 48 hours to obtain yeast-fermented garlic powder (yield 30 g).

試験例
(試験方法)
供試動物
本実験では、2匹の雄C57BL/6J及びBALB/cマウス(共に12週齢)から採精した。また、6匹の雌C57BL/6Jマウス(4週齢)から採卵した。
Test example (test method)
Test animals In this experiment, semen was collected from two male C57BL / 6J and BALB / c mice (both 12 weeks old). In addition, eggs were collected from 6 female C57BL / 6J mice (4 weeks old).

試薬及び培地
精子の前培養には、CARD FERTIUPTM精子前培養培地(九動、佐賀、日本)を使用した。卵子塊の前培養にはCARD MEDIUMTM高性能体外受精用培地(九動、佐賀、日本)を使用した。受精卵の培養にはCARD mHTF体外受精用培地(九動、佐賀、日本)を使用した。2細胞胚の培養にはKSOM-AA(MERCK、NJ、USA)を使用した。
Reagents and Medium CARD FERTIUP TM sperm preculture medium (Kyudo, Saga, Japan) was used for sperm preculture. CARD MEDIUM TM high-performance in vitro fertilization medium (Kyudo, Saga, Japan) was used for pre-culture of the egg mass. CARD mHTF in vitro fertilization medium (Kyudo, Saga, Japan) was used for culturing fertilized eggs. KSOM-AA (MERCK, NJ, USA) was used for culturing 2-cell embryos.

精子の採取
供試動物を頸椎脱臼により安楽死させた後、両側の精巣上体尾部を摘出し、付着した血液及び脂肪を取り除いた。ピンセットで精巣上体尾部を固定して、ノエス剪刀で尾部中央の精巣上体を切開した。精巣上体尾部切開部から精子塊を解剖針ですくい取り、FERTIUPTM精子前培養培地(九動、佐賀、日本)で30分間前培養(37℃、5%CO2、95% air)した後に、酵母発酵にんにく抽出液(1%)を含むFERTIUPTM精子前培養培地(九動、佐賀、日本)で60分間前培養(37℃、5%CO2、95% air)した。コントロールは、同様に30分間前培養(37℃、5%CO2、95% air)した後に、にんにく抽出液を含まないFERTIUPTM精子前培養培地(九動、佐賀、日本)で60分間前培養(37℃、5%CO2、95% air)した。
Sperm collection After the test animals were euthanized by cervical dislocation, the epididymal tails on both sides were removed to remove attached blood and fat. The epididymis tail was fixed with tweezers, and the epididymis in the center of the tail was incised with Noes scissors. After scooping the sperm mass from the epididymal tail incision with an anatomical needle and pre-culturing (37 ° C, 5% CO 2 , 95% air) in FERTIUP TM pre-culture medium (Kyudo, Saga, Japan) for 30 minutes. , FERTIUP TM sperm preculture medium (Kyudo, Saga, Japan) containing yeast fermented garlic extract (1%) was precultured for 60 minutes (37 ° C, 5% CO 2 , 95% air). Controls were similarly pre-cultured for 30 minutes (37 ° C, 5% CO 2 , 95% air) and then 60 minutes pre-cultured in FERTIUP TM sperm preculture medium (Kyudo, Saga, Japan) without garlic extract. (37 ° C, 5% CO 2 , 95% air).

卵子塊の採取
雌C57BL/6Jマウス(4週齢)に0.1mlのCARD HyperOvaTM過剰排卵誘起剤(九動、佐賀、日本)を腹腔内注射し、その48時間後に37.5IU/mlのヒト絨毛性性腺刺激ホルモンhCG(ゴナドトロピン、あすか製薬株式会社、東京、日本)を腹腔内注射して過剰排卵を誘発した。hCG投与の16時間後に過剰排卵させた雌マウスを頸椎脱臼により安楽死させて卵管を摘出し、細胞培養用流動パラフィン(ナカライテクス、京都、日本)内で卵管膨大部を開裂し、卵子塊を採取しCARD MEDIUMTM(九動、佐賀、日本)で前培養した。
Egg mass collection Female C57BL / 6J mice (4 weeks old ) were intraperitoneally injected with 0.1 ml of CARD HyperOva TM excess ovulation inducer (Kyudo, Saga, Japan), and 48 hours later, 37.5 IU / ml of human chorionic villi. Gonadotropin hCG (Gonadotropin, Asuka Pharmaceutical Co., Ltd., Tokyo, Japan) was intraperitoneally injected to induce excessive ovulation. 16 hours after administration of hCG, over-ovulated female mice were euthanized by cervical spinal cord dislocation to remove the fallopian tubes, and the ampulla of uterine tubes was cleaved in liquid paraffin for cell culture (Nakaraitex, Kyoto, Japan) to ova. Eggs were collected and precultured in CARD MEDIUM TM (Kyudo, Saga, Japan).

体外受精及び初期胚培養
前培養した精子と卵子塊を体外受精した(37℃、5%CO2、95% air)。3時間後、受精卵をCARD mHTF体外受精用培地(九動、佐賀、日本)で3回洗浄し、一晩培養した(37℃、5%CO2、95% air)。翌日、2細胞期胚をKSOM-AA(MERCK、NJ、USA)に移して3日間培養した(37℃、5%CO2、95% air)。
In vitro fertilization and early embryo culture Pre-cultured sperm and egg mass were in vitro fertilized (37 ° C, 5% CO 2 , 95% air). After 3 hours, the fertilized eggs were washed 3 times with CARD mHTF in vitro fertilization medium (Kyudo, Saga, Japan) and cultured overnight (37 ° C, 5% CO 2 , 95% air). The next day, 2-cell stage embryos were transferred to KSOM-AA (MERCK, NJ, USA) and cultured for 3 days (37 ° C, 5% CO 2 , 95% air).

受精率及び胚盤胞率
体外受精を実施した翌日に、2細胞期胚及び未受精卵、死亡卵をそれぞれカウントして受精率(%、2細胞期胚数/すべての細胞数)を算出した。また、2細胞期胚をKSOM-AA(MERCK、NJ、USA)に移して3日間培養し、胚盤胞及び2細胞期胚、死亡胚をそれぞれカウントして胚盤胞率(胚盤胞数/すべての胚数)及び2細胞期胚率(2細胞期胚数/すべての胚数)、死亡胚率(死亡胚数/すべての胚数)を算出した。
Fertilization rate and blastocyst rate On the day after in vitro fertilization, the fertilization rate (%, number of 2-cell stage embryos / number of all cells) was calculated by counting 2-cell stage embryos, unfertilized eggs, and dead eggs, respectively. .. In addition, 2-cell stage embryos are transferred to KSOM-AA (MERCK, NJ, USA) and cultured for 3 days, and blastocysts, 2-cell stage embryos, and dead embryos are counted, respectively, and the blastocyst rate (number of blastocysts). / Total number of embryos), 2-cell stage embryo rate (2-cell stage number of embryos / all number of embryos), and dead embryo rate (number of dead embryos / total number of embryos) were calculated.

統計解析
すべてのデータは平均±標準誤差(SEM)で表記した。統計解析はStudent t検定にて実施し、p<0.05を統計学的に有意であると判定した。
Statistical analysis All data are expressed as mean ± standard error (SEM). Statistical analysis was performed by Student's t-test, and p <0.05 was judged to be statistically significant.

(結果)
2細胞胚までの収率及び胚盤胞形成までの収率を図1に示す。
図1より、酵母発酵ニンニクの抽出物を添加して培養された受精卵は、2細胞胚までの割合はコントロールと比較して同等であった。一方、酵母発酵ニンニクの抽出物を添加して培養された受精卵は、胚盤胞までの形成率がコントロールに比べて有意に増加した。
従って、酵母発酵ニンニク又はその抽出物は、受精卵から胚盤胞への形成を促進させる作用を有することがわかった。
(result)
The yield up to 2-cell embryo and the yield up to blastocyst formation are shown in FIG.
From FIG. 1, the fertilized eggs cultured with the addition of the yeast fermented garlic extract had the same proportion up to the 2-cell embryo as compared with the control. On the other hand, in the fertilized eggs cultured with the addition of the yeast fermented garlic extract, the formation rate to the blastocyst was significantly increased as compared with the control.
Therefore, it was found that yeast-fermented garlic or an extract thereof has an action of promoting the formation of fertilized eggs into blastocysts.

Claims (4)

酵母発酵ニンニク又はその抽出物を含有する胚盤胞形成促進剤。 A blastocyst formation promoter containing yeast fermented garlic or an extract thereof. 受精卵から胚盤胞への形成促進剤である請求項1記載の胚盤胞形成促進剤。 The blastocyst formation promoter according to claim 1, which is a formation promoter from a fertilized egg to a blastocyst. 酵母発酵ニンニク又はその抽出物を含有する体外受精用培地。 In vitro fertilization medium containing yeast fermented garlic or an extract thereof. 酵母発酵ニンニク又はその抽出物を含有する培地中で卵子と精子を受精させ、次いで当該培地中で受精卵を培養することを特徴とする体外受精用胞胚又は胚盤胞の製造法。 A method for producing an in vitro fertilization blastocyst or blastocyst, which comprises fertilizing an egg and a sperm in a medium containing yeast fertilized garlic or an extract thereof, and then culturing the fertilized egg in the medium.
JP2020072222A 2020-04-14 2020-04-14 Blastocyst formation promoting agent Pending JP2021168603A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020072222A JP2021168603A (en) 2020-04-14 2020-04-14 Blastocyst formation promoting agent
CN202180025143.6A CN115605582A (en) 2020-04-14 2021-04-14 Blastocyst formation promoter
PCT/JP2021/015451 WO2021210609A1 (en) 2020-04-14 2021-04-14 Blastocyst formation promoting agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020072222A JP2021168603A (en) 2020-04-14 2020-04-14 Blastocyst formation promoting agent

Publications (1)

Publication Number Publication Date
JP2021168603A true JP2021168603A (en) 2021-10-28

Family

ID=78084582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020072222A Pending JP2021168603A (en) 2020-04-14 2020-04-14 Blastocyst formation promoting agent

Country Status (3)

Country Link
JP (1) JP2021168603A (en)
CN (1) CN115605582A (en)
WO (1) WO2021210609A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443070B2 (en) * 2000-04-26 2003-09-02 株式会社生物農業研究所 Method for deodorizing garlic and health food
KR101609918B1 (en) * 2014-04-22 2016-04-07 천현수 Manufacturing method of fermented garlic composition and the fermented garlic composition thereof

Also Published As

Publication number Publication date
CN115605582A (en) 2023-01-13
WO2021210609A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
WO2020013086A1 (en) Sperm fertility promoter
CN102783585A (en) Feed for improving reproductive performance of sows
WO2020262325A1 (en) Anti-aging agent for females
CN102488105A (en) Health care feed additive for farrowing sows and preparation method thereof
Figueira et al. Preovulatory follicular dynamics, ovulatory response and embryo yield in Lacaune ewes subjected to synchronous estrus induction protocols and non-surgical embryo recovery
Shabankareh et al. First service pregnancy rates following post‐AI use of hCG in ovsynch and heatsynch programmes in lactating dairy cows
WO2020258585A1 (en) Health food for improvement of female fertility and preparation method thereof
US11116801B2 (en) Composition containing endometrial decidual cells for treating damage to the endometrium or enhancing implantation functions
US20040067264A1 (en) Method of preparation and use of coconut water in mamalian tissue nourishment growth and healthy maintenance
WO2021210609A1 (en) Blastocyst formation promoting agent
JP5139294B2 (en) Pregnancy promoter
Vicente et al. Rabbit reproductive performance after insemination with buserelin acetate extender
KR101544783B1 (en) A composition comprising an extract of combined crude drugs for treating and preventing Male Infertility
KR101847497B1 (en) Pharmaceutical composition for preventing or treating of gynecologic disorders comprising extract of sarcodon asparatus as an ative ingredient
Sales et al. Effects of estradiol cypionate dosage and body condition on reproductive performance of Nellore cattle synchronized for timed-artificial insemination
CN109430553A (en) Improve sow breeding sexual dysfunction additive for microbe feedstuff and preparation method thereof
KR101742968B1 (en) Composition containing alpha-cyperone for improving pregnancy
WO2011045800A1 (en) Herbal compositions for inducing fertility in cattle
WO2021176479A1 (en) Composition for enhancing chances of conception and female sex ratio in bovines
Dudi et al. Efficacy of different estrus synchronizing protocols on estrus induction in postpartum lactating dairy cows
Omontese et al. Oestrus behaviour and conception rates of red sokoto goats following treatment with equine chorionic Gonadotrophin and Prostaglandin
Atmoko et al. Estrous response of Etawah Crossbred does on estrous synchronization using the prostaglandin f2α based protocol
CN107075474A (en) The undifferentiated state of stem cell maintains agent and enhancer of proliferation
CN113973999B (en) Fermented compound traditional Chinese medicine additive for improving water content and PSY of sows and sheep and preparation method thereof
KR101667242B1 (en) Composition containing paeonol for preventing or treating infertility

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528